Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
198 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016', provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD) - The report reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Attention Deficit Hyperactivity Disorder (ADHD) therapeutics and enlists all their major and minor projects - The report assesses Attention Deficit Hyperactivity Disorder (ADHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Attention Deficit Hyperactivity Disorder (ADHD) Overview 9 Therapeutics Development 10 Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview 10 Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis 11 Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies 12 Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes 16 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies 21 Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes 25 Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development 26 Alcobra Ltd 26 Amarantus Bioscience Holdings, Inc. 27 APeT Holding BV 28 Arbor Pharmaceuticals, LLC 29 BCWorld Pharm Co. Ltd. 30 BioLite, Inc. 31 Collegium Pharmaceutical, Inc. 32 Curemark, LLC 33 DURECT Corporation 34 Egalet Corporation 35 Eli Lilly and Company 36 Ensysce Biosciences Inc. 37 H. Lundbeck A/S 38 Heptares Therapeutics Limited 39 Highland Therapeutics, Inc. 40 Integrative Research Laboratories Sweden AB 41 Intra-Cellular Therapies, Inc. 42 INVENT Pharmaceuticals, Inc. 43 KemPharm, Inc. 44 Luc Therapeutics, Inc. 45 Medgenics, Inc. 46 Merck & Co., Inc. 47 Neos Therapeutics, Inc. 48 NeuroDerm Ltd. 49 Neurovance, Inc. 50 NLS Pharma Group 51 Noven Pharmaceuticals, Inc. 52 P2D Bioscience 53 Polleo Pharma Limited 54 Reviva Pharmaceuticals Inc. 55 Shire Plc 56 Sunovion Pharmaceuticals Inc. 57 Supernus Pharmaceuticals, Inc. 58 Taisho Pharmaceutical Co., Ltd. 59 Taisho Pharmaceutical Holdings Co., Ltd. 60 TRImaran Pharma, Inc. 61 Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment 62 Assessment by Monotherapy Products 62 Assessment by Combination Products 63 Assessment by Target 64 Assessment by Mechanism of Action 67 Assessment by Route of Administration 70 Assessment by Molecule Type 72 Drug Profiles 74 (nicotine + opipramol hydrochloride) - Drug Profile 74 AR-08 - Drug Profile 75 BCWPE-003 - Drug Profile 76 BLI-1008 - Drug Profile 77 BNC-375 - Drug Profile 78 CB-8411 - Drug Profile 79 centanafadine IR - Drug Profile 80 centanafadine SR - Drug Profile 81 CM-4612 - Drug Profile 84 CTX-1301 - Drug Profile 85 CTX-1302 - Drug Profile 86 dasotraline hydrochloride - Drug Profile 87 dextroamphetamine - Drug Profile 89 dextroamphetamine MR - Drug Profile 90 edivoxetine hydrochloride - Drug Profile 92 Egalet-003 - Drug Profile 94 eltoprazine - Drug Profile 95 etiguanfacine - Drug Profile 100 fasoracetam - Drug Profile 101 guanfacine hydrochloride ER - Drug Profile 103 histamine dihydrochloride - Drug Profile 105 HTL-1071 - Drug Profile 106 INV-107 - Drug Profile 108 INV-170 - Drug Profile 109 IRL-752 - Drug Profile 110 ITI-214 - Drug Profile 111 KP-415 CR - Drug Profile 113 lisdexamfetamine dimesylate - Drug Profile 115 mazindol - Drug Profile 122 Metadoxine ER - Drug Profile 123 methylphenidate hydrochloride ER - Drug Profile 130 methylphenidate hydrochloride MR - Drug Profile 131 methylphenidate hydrochloride SR - Drug Profile 135 methylphenidate hydrochloride XR - Drug Profile 137 MGS-0028 - Drug Profile 139 molindone hydrochloride ER - Drug Profile 140 niacinamide CR - Drug Profile 142 NLS-3 - Drug Profile 143 NLS-4 - Drug Profile 144 NT-0201 - Drug Profile 145 P-001 - Drug Profile 146 PBF-509 - Drug Profile 147 PD-2005 - Drug Profile 148 PD-3044 - Drug Profile 149 PFR-08001 - Drug Profile 150 PFR-8026 - Drug Profile 151 RP-5063 - Drug Profile 152 SHP-465 - Drug Profile 154 Small Molecule to Block Dopamine, Norepinephrine and Serotonin Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile 156 Small Molecules for Attention Deficit Hyperactivity Disorder - Drug Profile 157 Small Molecules to Agonize NMDA2D for Attention Deficit Hyperactivity Disorder - Drug Profile 158 Small Molecules to Inhibit Dopamine Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile 159 Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 160 Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile 161 Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile 162 Small Molecules to Modulate Choline Transporter for ADHD - Drug Profile 163 Synthetic Peptide to Antagonize D2 for ADHD - Drug Profile 164 TS-141 - Drug Profile 165 Vaccine for CNS Disorders - Drug Profile 166 viloxazine hydrochloride ER - Drug Profile 167 vortioxetine hydrobromide - Drug Profile 168 VU-0238429 - Drug Profile 174 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects 175 Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products 180 Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones 181 Featured News & Press Releases 181 Appendix 193 Methodology 193 Coverage 193 Secondary Research 193 Primary Research 193 Expert Panel Validation 193 Contact Us 193 Disclaimer 194
List of Tables
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2016 14 Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, H2 2016 15 Number of Products under Development by Companies, H2 2016 17 Number of Products under Development by Companies, H2 2016 (Contd..1) 18 Number of Products under Development by Companies, H2 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2016 20 Comparative Analysis by Late Stage Development, H2 2016 21 Comparative Analysis by Clinical Stage Development, H2 2016 22 Comparative Analysis by Early Stage Development, H2 2016 23 Comparative Analysis by Unknown Stage Development, H2 2016 24 Products under Development by Companies, H2 2016 25 Products under Development by Companies, H2 2016 (Contd..1) 26 Products under Development by Companies, H2 2016 (Contd..2) 27 Products under Development by Companies, H2 2016 (Contd..3) 28 Products under Investigation by Universities/Institutes, H2 2016 29 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd, H2 2016 30 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 31 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV, H2 2016 32 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals, LLC, H2 2016 33 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co. Ltd., H2 2016 34 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioLite, Inc., H2 2016 35 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical, Inc., H2 2016 36 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark, LLC, H2 2016 37 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corporation, H2 2016 38 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Egalet Corporation, H2 2016 39 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Company, H2 2016 40 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Ensysce Biosciences Inc., H2 2016 41 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by H. Lundbeck A/S, H2 2016 42 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Heptares Therapeutics Limited, H2 2016 43 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics, Inc., H2 2016 44 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016 45 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Intra-Cellular Therapies, Inc., H2 2016 46 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 47 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm, Inc., H2 2016 48 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Luc Therapeutics, Inc., H2 2016 49 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Medgenics, Inc., H2 2016 50 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co., Inc., H2 2016 51 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics, Inc., H2 2016 52 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd., H2 2016 53 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neurovance, Inc., H2 2016 54 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NLS Pharma Group, H2 2016 55 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Noven Pharmaceuticals, Inc., H2 2016 56 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience, H2 2016 57 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Polleo Pharma Limited, H2 2016 58 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc., H2 2016 59 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc, H2 2016 60 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016 61 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals, Inc., H2 2016 62 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2016 63 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016 64 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by TRImaran Pharma, Inc., H2 2016 65 Assessment by Monotherapy Products, H2 2016 66 Assessment by Combination Products, H2 2016 67 Number of Products by Stage and Target, H2 2016 69 Number of Products by Stage and Mechanism of Action, H2 2016 72 Number of Products by Stage and Route of Administration, H2 2016 75 Number of Products by Stage and Molecule Type, H2 2016 77 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2016 179 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..1), H2 2016 180 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..2), H2 2016 181 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..3), H2 2016 182 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..4), H2 2016 183 Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, H2 2016 184
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
